2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1
2016
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer
Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. American Journal Of Clinical Oncology 2016, 39: 18-26. PMID: 24351782, PMCID: PMC4061284, DOI: 10.1097/coc.0000000000000022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapyCohort StudiesDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansInduction ChemotherapyMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsProportional Hazards ModelsRetrospective StudiesSex FactorsTime FactorsTreatment OutcomeConceptsAdvanced pancreatic cancerCycles of chemotherapyOverall survivalInduction chemotherapyPancreatic cancerMedian overall survivalRole of chemotherapyTreatment of LAPCUnresectable stage 3Better survival outcomesBetter overall survivalCombination of chemotherapyJohns Hopkins HospitalSensitization of tumorsConsolidative chemoradiationSubsequent chemoradiationCombination chemotherapyCumulative incidenceProspective studySurvival outcomesStandard treatmentDisease progressionChemoradiationRetrospective analysisChemotherapy